arsenic has been researched along with Minimal Disease, Residual in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Cheng, Y; Liu, G; Lu, A; Wang, B; Wu, J; Zhang, L | 1 |
| Grimwade, D; Hills, RK; Jovanovic, JV | 1 |
| Feusner, JH; Gregory, J; Kutny, MA | 1 |
| Gore, SD; Zeidan, AM | 1 |
| Angell, R; Aslett, H; Batson, E; Burnett, AK; Clark, RE; Diverio, D; Flora, R; Grimwade, D; Hills, RK; Jones, K; Jovanovic, JV; Lo-Coco, F; Nugent, EA; Patel, Y; Rennie, K; Solomon, E; Wheatley, K | 1 |
| Grimwade, D; Guidez, F; Mistry, AR; Solomon, E | 1 |
| Abraham, A; Ahmed, R; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Ganesan, S; George, B; Janet, NB; Lakshmi, KM; Mathews, V; Nair, SC; Sitaram, U; Srivastava, A; Srivastava, VM; Viswabandya, A | 1 |
| Cao, Z; Li, Q; Ruan, M; Wang, J; Zhang, L; Zhu, X; Zou, Y | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Rossi, M; Visani, G | 1 |
| Aghdami, N; Alimoghaddam, K; Bahar, B; Baybordi, E; Ghaffari, SH; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Khodabadeh, A; Mortazavi, Y; Mossavi, A; Rostami, S; Totonchi, M | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A | 1 |
| Au, WY; Chan, CH; Chim, CS; Fung, AT; Kwong, YL; Liang, RH; Ma, ES; Wong, KF | 1 |
| Bonapace, L; Bornhauser, BC; Bourquin, JP; Cario, G; Lindholm, D; Martinez, R; Niggli, FK; Schäfer, BW; Schrappe, M | 1 |
| Avvisati, G; Lo Coco, F; Mandelli, F; Nervi, C | 1 |
| Powell, BL | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Pang, A; Suen, C | 1 |
| Douer, D | 1 |
| Chen, Z; Wang, ZY | 1 |
8 review(s) available for arsenic and Minimal Disease, Residual
| Article | Year |
|---|---|
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Differentiation; Clinical Trials as Topic; Disease Management; Drug Monitoring; Drug Resistance, Neoplasm; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Real-Time Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Tretinoin | 2014 |
Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin | 2014 |
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Management; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Tretinoin | 2014 |
Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dyspnea; Fever; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Models, Biological; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Treatment Outcome; Tretinoin | 2010 |
Treatment concepts of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2005 |
Acute progranulocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Prognosis; Salvage Therapy; Survival Analysis; Tretinoin | 2001 |
Advances in the treatment of relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Recurrence; Tretinoin | 2002 |
Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Tretinoin | 2000 |
11 other study(ies) available for arsenic and Minimal Disease, Residual
| Article | Year |
|---|---|
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Neoplasm, Residual; Oxides; Prognosis; Treatment Outcome; Tretinoin | 2013 |
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Bone Marrow; Cohort Studies; Confidence Intervals; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tretinoin | 2009 |
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Monitoring, Physiologic; Neoadjuvant Therapy; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2012 |
Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Multivariate Analysis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Transcription, Genetic; Treatment Outcome; Tretinoin | 2012 |
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2003 |
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Treatment Outcome | 2006 |
Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Humans; Leukemia, Promyelocytic, Acute; Methylation; Neoplasm, Residual; Oxides; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Blotting, Western; Caspases; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Glucocorticoids; Humans; Neoplasm, Residual; Oxides; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Remission Induction; RNA, Small Interfering; Signal Transduction; Sirolimus; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Acute promyelocytic leukemia: a curable disease.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Karyotyping; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Research; Rome; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1998 |
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Evaluation; Drug Synergism; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Pilot Projects; Prospective Studies; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Treatment Outcome | 2001 |